Establishing a Target Exposure for Once-Daily Intravenous Busulfan Given with Fludarabine and Thymoglobulin before Allogeneic Transplantation
Authors:
- James A. RussellJRJames A. Russell
- Shahbal B. KangarlooSKShahbal B. Kangarloo
- Tyler WilliamsonTWTyler Williamson
- M. Ahsan ChaudhryMCM. Ahsan Chaudhry
- Mary Lynn SavoieMSMary Lynn Savoie
- A. Robert TurnerATA. Robert Turner
- Loree LarrattLLLoree Larratt
- Jan StorekJSJan Storek
- Nizar J. BahlisNBNizar J. Bahlis
- Mona ShafeyMSMona Shafey
- Christopher B. BrownCBChristopher B. Brown
- Maggie YangMYMaggie Yang
Open Access
- 1 September 2013
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 19 (9) , 1381-1386
Abstract
No abstract availableKeywords
Funding Information
- Otsuka Pharma
This publication has 22 references indexed in Scilit:
- Maximally Tolerated Busulfan Systemic Exposure in Combination with Fludarabine as Conditioning before Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2012
- Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of LifeTransplantation and Cellular Therapy, 2011
- Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complicationsInternational Journal of Hematology, 2011
- Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemiaJournal of Hematology & Oncology, 2010
- Therapeutic Drug Monitoring of Busulfan in TransplantationCurrent Pharmaceutical Design, 2008
- Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDSTransplantation and Cellular Therapy, 2008
- Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine, 400 CGY Total-Body Irradiation, and ThymoglobulinTransplantation and Cellular Therapy, 2007
- Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower Mortality Related to Graft-versus-Host Disease: A Matched Pair AnalysisTransplantation and Cellular Therapy, 2007
- Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSBlood, 2004
- Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomesTransplantation and Cellular Therapy, 2002